Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho/Fibroblast Growth Factor 23 System
- PMID: 36406946
- PMCID: PMC9635803
- DOI: 10.14740/jocmr4820
Current and Future Therapeutical Aspects of X-Linked Hypophosphatemia in Children With Special Attention to Klotho/Fibroblast Growth Factor 23 System
Conflict of interest statement
There is no conflict of interest.
Similar articles
-
FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.J Cell Physiol. 2017 Mar;232(3):610-616. doi: 10.1002/jcp.25458. Epub 2016 Jun 30. J Cell Physiol. 2017. PMID: 27306296
-
[Bone and joint diseases in children. Phosphaturic hormone, FGF23, and bone metabolism].Clin Calcium. 2010 Jun;20(6):896-903. Clin Calcium. 2010. PMID: 20513948 Review. Japanese.
-
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.N Engl J Med. 2003 Apr 24;348(17):1656-63. doi: 10.1056/NEJMoa020881. N Engl J Med. 2003. PMID: 12711740
-
Targeted inhibition of Klotho binding to fibroblast growth factor 23 prevents hypophosphetemia.J Mol Graph Model. 2017 Aug;75:9-19. doi: 10.1016/j.jmgm.2017.04.024. Epub 2017 Apr 27. J Mol Graph Model. 2017. PMID: 28501532
-
FGF23 and its role in X-linked hypophosphatemia-related morbidity.Orphanet J Rare Dis. 2019 Feb 26;14(1):58. doi: 10.1186/s13023-019-1014-8. Orphanet J Rare Dis. 2019. PMID: 30808384 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources